Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:LUCD NASDAQ:PDEX NASDAQ:SMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$10.14+6.7%$10.28$8.56▼$14.76$55.46M0.272,162 shs2,812 shsLUCDLucid Diagnostics$1.03$1.07$0.90▼$1.63$209.16M1.081.21 million shs988,950 shsPDEXPro-Dex$63.39-1.6%$59.39$23.47▼$68.99$205.61M-0.0264,225 shs80,421 shsSMTISanara MedTech$21.75$21.03$16.05▼$35.95$199.32M1.2154,956 shs61,595 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+4.05%+1.40%-4.11%-2.41%+7.19%LUCDLucid Diagnostics0.00%+0.98%-3.74%-13.45%-13.45%PDEXPro-Dex-1.57%+1.72%-0.20%+30.41%+51.58%SMTISanara MedTech0.00%-4.14%-6.13%+33.11%-21.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$10.14+6.7%$10.28$8.56▼$14.76$55.46M0.272,162 shs2,812 shsLUCDLucid Diagnostics$1.03$1.07$0.90▼$1.63$209.16M1.081.21 million shs988,950 shsPDEXPro-Dex$63.39-1.6%$59.39$23.47▼$68.99$205.61M-0.0264,225 shs80,421 shsSMTISanara MedTech$21.75$21.03$16.05▼$35.95$199.32M1.2154,956 shs61,595 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+4.05%+1.40%-4.11%-2.41%+7.19%LUCDLucid Diagnostics0.00%+0.98%-3.74%-13.45%-13.45%PDEXPro-Dex-1.57%+1.72%-0.20%+30.41%+51.58%SMTISanara MedTech0.00%-4.14%-6.13%+33.11%-21.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 2.50Moderate BuyN/AN/ALUCDLucid Diagnostics 2.60Moderate Buy$4.19306.55% UpsidePDEXPro-Dex 2.33Hold$70.0010.43% UpsideSMTISanara MedTech 2.60Moderate Buy$34.0056.32% UpsideCurrent Analyst Ratings BreakdownLatest DXR, LUCD, SMTI, and PDEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026SMTISanara MedTech Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/10/2026SMTISanara MedTech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/8/2026LUCDLucid Diagnostics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $9.255/19/2026PDEXPro-Dex Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LUCDLucid Diagnostics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/15/2026LUCDLucid Diagnostics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.505/12/2026PDEXPro-Dex Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.005/12/2026SMTISanara MedTech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/6/2026LUCDLucid Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/1/2026PDEXPro-Dex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/21/2026SMTISanara MedTech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxor$10.30M5.75N/AN/AN/A∞LUCDLucid Diagnostics$4.71M44.41N/AN/A($0.31) per share-3.32PDEXPro-Dex$66.59M3.04$3.09 per share20.54$11.23 per share5.64SMTISanara MedTech$103.12M1.93$0.59 per share36.58$0.67 per share32.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/A8/20/2026 (Estimated)LUCDLucid Diagnostics-$58.01M-$0.47N/AN/AN/A-876.72%N/A-116.26%8/12/2026 (Estimated)PDEXPro-Dex$8.98M$3.6217.5122.80N/A16.08%22.78%14.30%7/8/2026 (Estimated)SMTISanara MedTech-$37.56M-$3.77N/AN/AN/A-31.23%-3.19%-0.56%8/12/2026 (Estimated)Latest DXR, LUCD, SMTI, and PDEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LUCDLucid Diagnostics-$0.05-$0.07-$0.02-$0.17$1.38 million$1.26 million4/30/2026Q3 2026PDEXPro-Dex$0.62$1.20+$0.58$1.20$17.90 million$19.95 million3/25/2026Q4 2025LUCDLucid Diagnostics-$0.07-$0.10-$0.03-$0.12$1.39 million$1.50 million3/24/2026Q4 2025SMTISanara MedTech$0.11$0.04-$0.07-$0.19$27.90 million$27.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxor$0.030.30%N/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/ALUCDLucid DiagnosticsN/A1.071.05PDEXPro-Dex0.323.672.14SMTISanara MedTech6.592.282.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%LUCDLucid Diagnostics74.01%PDEXPro-Dex15.28%SMTISanara MedTech8.10%Insider OwnershipCompanyInsider OwnershipDXRDaxor51.50%LUCDLucid Diagnostics6.90%PDEXPro-Dex45.90%SMTISanara MedTech42.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor375.84 million2.83 millionNot OptionableLUCDLucid Diagnostics70203.07 million189.06 millionNo DataPDEXPro-Dex1403.19 million1.73 millionNot OptionableSMTISanara MedTech609.16 million5.32 millionNot OptionableDXR, LUCD, SMTI, and PDEX HeadlinesRecent News About These CompaniesSanara MedTech (SMTI) Stock Gets Fair Value Bump As Analysts Back Wound Care GrowthJune 23 at 2:55 PM | finance.yahoo.comSanara MedTech Earnings Call Signals Profitable GrowthJune 12, 2026 | theglobeandmail.comSanara MedTech (SMTI) Q1 2026 Earnings TranscriptJune 2, 2026 | fool.comHow The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays PutMay 23, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 21, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 19, 2026 | globenewswire.comSanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 14, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 14, 2026 | prnewswire.comSanara MedTech: From Cash Burner To Profitable GrowthMay 14, 2026 | seekingalpha.comSanara MedTech Inc (SMTI) Q1 2026 Earnings Report Preview: What To ExpectMay 13, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 12, 2026 | globenewswire.comSanara MedTech Inc. (SMTI) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)May 11, 2026 | globenewswire.comSMTI Investors Have Opportunity to Join Sanara MedTech Inc. Fraud Investigation with the Schall Law FirmMay 7, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 7, 2026 | prnewswire.comHow Sanara MedTech (SMTI) Is Reframing Its Growth Story Around A Steady US$34 TargetMay 5, 2026 | finance.yahoo.comSanara MedTech (SMTI) Q4 2025 Earnings TranscriptMay 4, 2026 | fool.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIApril 28, 2026 | globenewswire.comWhat Makes Sanara Medtech (SMTI) A Compelling Risk-Reward Opportunity?April 23, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXR, LUCD, SMTI, and PDEX Company DescriptionsDaxor NASDAQ:DXR$10.14 +0.64 (+6.74%) As of 06/23/2026 03:27 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Lucid Diagnostics NASDAQ:LUCD$1.03 0.00 (0.00%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$1.04 +0.01 (+0.78%) As of 07:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Pro-Dex NASDAQ:PDEX$63.39 -1.01 (-1.57%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$63.39 0.00 (0.00%) As of 06:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Sanara MedTech NASDAQ:SMTI$21.75 0.00 (0.00%) As of 06/23/2026 04:00 PM EasternSanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
